Palisades Investment initiated a position in Travere Therapeutics worth more than $5 million. Is the stock a buy?
Palisades added 137,768 shares of Travere Therapeutics; Estimated business size of $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (AUM). Travere Therapeutics is not among the fund’s top five holdings after the trade. These 10 stocks could generate the next wave of millionaires › According to a…